Cargando…
Oncolytic adenovirus armed with IL-24 Inhibits the growth of breast cancer in vitro and in vivo
BACKGROUND: Interleukin-24 (IL-24) is a cytokine that belongs to the IL-10 family. It can selectively induce cancer cell apoptosis which has been utilized as a cancer gene therapy strategy. METHODS: A recombinant type five adenovirus containing IL-24 gene (designated CNHK600-IL24) was constructed, w...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3511263/ https://www.ncbi.nlm.nih.gov/pubmed/22640485 http://dx.doi.org/10.1186/1756-9966-31-51 |
_version_ | 1782251568613031936 |
---|---|
author | Zhu, Wei Wei, Lai Zhang, Hongwei Chen, Junxue Qin, Xinyu |
author_facet | Zhu, Wei Wei, Lai Zhang, Hongwei Chen, Junxue Qin, Xinyu |
author_sort | Zhu, Wei |
collection | PubMed |
description | BACKGROUND: Interleukin-24 (IL-24) is a cytokine that belongs to the IL-10 family. It can selectively induce cancer cell apoptosis which has been utilized as a cancer gene therapy strategy. METHODS: A recombinant type five adenovirus containing IL-24 gene (designated CNHK600-IL24) was constructed, whose replication is activated only in tumor cells. The replication of CNHK600-IL24 in breast tumor cells and fibroblasts were assessed by TCID50 and MTT assay; the secretion of IL-24 was measured by ELISA and western blotting. The in vivo anti-tumor effect of CNHK600-IL24 was investigated in nude mice carrying orthotopic or metastatic breast tumor. RESULTS: We observed that CNHK600-IL24 could replicate efficiently and resulted in high level IL-24 expression and massive cell death in human breast cancer cell MDA-MB-231 but not in normal fibroblast cell MRC-5. In addition, orthotopic breast tumor growth in the nude mice model was significantly suppressed when CNHK600-IL24 was administered. In the metastatic model generated by tail vein injection, CNHK600-IL24 virotherapy significantly improved survival compared with the same virus expressing EGFP (median survival CNHK600-IL24, 55 days vs. CNHK600-EGFP, 41 day, p < 0.05 Mantal-Cox test). A similar phenomenon was observed in the metastatic model achieved by left ventricular injection as suggested by in vivo luminescence imaging of tumor growth. CONCLUSION: The oncolytic adenovirus armed with IL-24, which exhibited enhanced anti-tumor activity and improved survival, is a promising candidate for virotherapy of breast cancer. |
format | Online Article Text |
id | pubmed-3511263 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35112632012-12-01 Oncolytic adenovirus armed with IL-24 Inhibits the growth of breast cancer in vitro and in vivo Zhu, Wei Wei, Lai Zhang, Hongwei Chen, Junxue Qin, Xinyu J Exp Clin Cancer Res Research BACKGROUND: Interleukin-24 (IL-24) is a cytokine that belongs to the IL-10 family. It can selectively induce cancer cell apoptosis which has been utilized as a cancer gene therapy strategy. METHODS: A recombinant type five adenovirus containing IL-24 gene (designated CNHK600-IL24) was constructed, whose replication is activated only in tumor cells. The replication of CNHK600-IL24 in breast tumor cells and fibroblasts were assessed by TCID50 and MTT assay; the secretion of IL-24 was measured by ELISA and western blotting. The in vivo anti-tumor effect of CNHK600-IL24 was investigated in nude mice carrying orthotopic or metastatic breast tumor. RESULTS: We observed that CNHK600-IL24 could replicate efficiently and resulted in high level IL-24 expression and massive cell death in human breast cancer cell MDA-MB-231 but not in normal fibroblast cell MRC-5. In addition, orthotopic breast tumor growth in the nude mice model was significantly suppressed when CNHK600-IL24 was administered. In the metastatic model generated by tail vein injection, CNHK600-IL24 virotherapy significantly improved survival compared with the same virus expressing EGFP (median survival CNHK600-IL24, 55 days vs. CNHK600-EGFP, 41 day, p < 0.05 Mantal-Cox test). A similar phenomenon was observed in the metastatic model achieved by left ventricular injection as suggested by in vivo luminescence imaging of tumor growth. CONCLUSION: The oncolytic adenovirus armed with IL-24, which exhibited enhanced anti-tumor activity and improved survival, is a promising candidate for virotherapy of breast cancer. BioMed Central 2012-05-28 /pmc/articles/PMC3511263/ /pubmed/22640485 http://dx.doi.org/10.1186/1756-9966-31-51 Text en Copyright ©2012 Zhu et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Zhu, Wei Wei, Lai Zhang, Hongwei Chen, Junxue Qin, Xinyu Oncolytic adenovirus armed with IL-24 Inhibits the growth of breast cancer in vitro and in vivo |
title | Oncolytic adenovirus armed with IL-24 Inhibits the growth of breast cancer in vitro and in vivo |
title_full | Oncolytic adenovirus armed with IL-24 Inhibits the growth of breast cancer in vitro and in vivo |
title_fullStr | Oncolytic adenovirus armed with IL-24 Inhibits the growth of breast cancer in vitro and in vivo |
title_full_unstemmed | Oncolytic adenovirus armed with IL-24 Inhibits the growth of breast cancer in vitro and in vivo |
title_short | Oncolytic adenovirus armed with IL-24 Inhibits the growth of breast cancer in vitro and in vivo |
title_sort | oncolytic adenovirus armed with il-24 inhibits the growth of breast cancer in vitro and in vivo |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3511263/ https://www.ncbi.nlm.nih.gov/pubmed/22640485 http://dx.doi.org/10.1186/1756-9966-31-51 |
work_keys_str_mv | AT zhuwei oncolyticadenovirusarmedwithil24inhibitsthegrowthofbreastcancerinvitroandinvivo AT weilai oncolyticadenovirusarmedwithil24inhibitsthegrowthofbreastcancerinvitroandinvivo AT zhanghongwei oncolyticadenovirusarmedwithil24inhibitsthegrowthofbreastcancerinvitroandinvivo AT chenjunxue oncolyticadenovirusarmedwithil24inhibitsthegrowthofbreastcancerinvitroandinvivo AT qinxinyu oncolyticadenovirusarmedwithil24inhibitsthegrowthofbreastcancerinvitroandinvivo |